Sam Chun Dang Pharm. Co. Ltd

KQ:000250 Korea Pharmaceuticals
Market Cap
$10.80 Billion
₩15.82 Trillion KRW
Market Cap Rank
#3465 Global
#66 in Korea
Share Price
₩739000.00
Change (1 day)
+1.23%
52-Week Range
₩130900.00 - ₩825000.00
All Time High
₩825000.00
Categories
Companies in Korea Pharmaceuticals
About

Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more

Sam Chun Dang Pharm. Co. Ltd (000250) - Net Assets

Latest net assets as of September 2025: ₩354.99 Billion KRW

Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has net assets worth ₩354.99 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩529.96 Billion) and total liabilities (₩174.97 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩354.99 Billion
% of Total Assets 66.98%
Annual Growth Rate 9.8%
5-Year Change 42.59%
10-Year Change 132.78%
Growth Volatility 22.94

Sam Chun Dang Pharm. Co. Ltd - Net Assets Trend (2012–2024)

This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sam Chun Dang Pharm. Co. Ltd (2012–2024)

The table below shows the annual net assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024.

Year Net Assets Change
2024-12-31 ₩266.11 Billion -10.84%
2023-12-31 ₩298.46 Billion +71.78%
2022-12-31 ₩173.74 Billion -0.20%
2021-12-31 ₩174.09 Billion -6.71%
2020-12-31 ₩186.63 Billion +18.21%
2019-12-31 ₩157.87 Billion +6.30%
2018-12-31 ₩148.52 Billion +5.08%
2017-12-31 ₩141.34 Billion +12.92%
2016-12-31 ₩125.17 Billion +9.49%
2015-12-31 ₩114.32 Billion -18.16%
2014-12-31 ₩139.68 Billion +17.15%
2013-12-31 ₩119.23 Billion +37.63%
2012-12-31 ₩86.63 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Sam Chun Dang Pharm. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 66.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩95.45 Billion 35.87%
Common Stock ₩11.73 Billion 4.41%
Other Components ₩158.92 Billion 59.72%
Total Equity ₩266.11 Billion 100.00%

Sam Chun Dang Pharm. Co. Ltd Competitors by Market Cap

The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their market capitalization.

Company Market Cap
Wan Hai Lines Ltd
TW:2615
 		$3.69 Billion
Swissquote Group Holding Ltd
PINK:SWQGF
 		$3.69 Billion
Sodexo SA
PA:SW
 		$3.69 Billion
Hangzhou Silan Microelectronics Co Ltd
SHG:600460
 		$3.70 Billion
MIRUM PHARMAC. DL-0001
F:08D
 		$3.69 Billion
Great-West Lifeco Inc 4.50% Non-Cum 1st Pfd Shs Ser I
PINK:GRWTF
 		$3.69 Billion
Globalstar Inc
NYSE MKT:GSAT
 		$3.69 Billion
Lifco AB (publ)
PINK:LFCBY
 		$3.69 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sam Chun Dang Pharm. Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 220,498,640,040 to 266,105,335,240, a change of 45,606,695,200 (20.7%).
  • Net loss of 10,916,104,970 reduced equity.
  • Dividend payments of 890,150,900 reduced retained earnings.
  • Share repurchases of 71,215,115,460 reduced equity.
  • New share issuances of 71,215,115,450 increased equity.
  • Other factors increased equity by 57,412,951,080.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-10.92 Billion -4.1%
Dividends Paid ₩890.15 Million -0.33%
Share Repurchases ₩71.22 Billion -26.76%
Share Issuances ₩71.22 Billion +26.76%
Other Changes ₩57.41 Billion +21.58%
Total Change ₩- 20.68%

Book Value vs Market Value Analysis

This analysis compares Sam Chun Dang Pharm. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 64.59x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 125.76x to 64.59x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩5876.20 ₩739000.00 x
2017-12-31 ₩6602.83 ₩739000.00 x
2018-12-31 ₩6938.23 ₩739000.00 x
2019-12-31 ₩7375.20 ₩739000.00 x
2020-12-31 ₩8456.84 ₩739000.00 x
2021-12-31 ₩7889.00 ₩739000.00 x
2022-12-31 ₩7872.97 ₩739000.00 x
2023-12-31 ₩9718.51 ₩739000.00 x
2024-12-31 ₩11441.71 ₩739000.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sam Chun Dang Pharm. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -4.10%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -5.18%
  • • Asset Turnover: 0.41x
  • • Equity Multiplier: 1.95x
  • Recent ROE (-4.10%) is below the historical average (3.48%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 1.63% 1.75% 0.63x 1.49x ₩-6.87 Billion
2013 9.37% 8.34% 0.67x 1.67x ₩-588.58 Million
2014 11.24% 9.96% 0.69x 1.64x ₩1.30 Billion
2015 10.17% 8.81% 0.72x 1.61x ₩196.52 Million
2016 6.96% 5.91% 0.72x 1.64x ₩-3.80 Billion
2017 8.85% 7.79% 0.70x 1.63x ₩-1.62 Billion
2018 5.89% 5.47% 0.61x 1.76x ₩-6.10 Billion
2019 6.62% 5.60% 0.64x 1.84x ₩-5.34 Billion
2020 -0.52% -0.58% 0.53x 1.70x ₩-19.63 Billion
2021 -9.51% -9.90% 0.48x 1.99x ₩-33.96 Billion
2022 3.36% 3.29% 0.48x 2.15x ₩-11.54 Billion
2023 -4.71% -5.39% 0.47x 1.85x ₩-32.43 Billion
2024 -4.10% -5.18% 0.41x 1.95x ₩-37.53 Billion

Industry Comparison

This section compares Sam Chun Dang Pharm. Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $94,183,171,268
  • Average return on equity (ROE) among peers: -11.71%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sam Chun Dang Pharm. Co. Ltd (000250) ₩354.99 Billion 1.63% 0.49x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Sam-A Pharm. Co. Ltd (009300) $148.92 Billion 6.63% 0.09x $21.27 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $257.20 Billion 4.73% 0.21x $50.06 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million